0000899243-20-035444.txt : 20201229 0000899243-20-035444.hdr.sgml : 20201229 20201229211453 ACCESSION NUMBER: 0000899243-20-035444 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201228 FILED AS OF DATE: 20201229 DATE AS OF CHANGE: 20201229 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Turtle Cameron CENTRAL INDEX KEY: 0001758363 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38959 FILM NUMBER: 201423828 MAIL ADDRESS: STREET 1: C/O EIDOS THERAPEUTICS, INC. STREET 2: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BridgeBio Pharma, Inc. CENTRAL INDEX KEY: 0001743881 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 BUSINESS PHONE: (650) 391-9740 MAIL ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 FORMER COMPANY: FORMER CONFORMED NAME: BridgeBio Pharma LLC DATE OF NAME CHANGE: 20180618 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-28 0 0001743881 BridgeBio Pharma, Inc. BBIO 0001758363 Turtle Cameron C/O BRIDGEBIO PHARMA, INC. 421 KIPLING STREET PALO ALTO CA 94301 0 1 0 0 See Remarks Common Stock 2020-12-28 4 M 0 7500 17.00 A 20068 D Common Stock 2020-12-28 4 M 0 6000 0.34 A 26068 D Common Stock 2020-12-28 4 M 0 6000 0.16 A 32068 D Common Stock 2020-12-28 4 S 0 10937 69.3361 D 21131 D Common Stock 2020-12-28 4 S 0 8563 69.9352 D 12568 D Stock Option (Right to Buy) 17.00 2020-12-28 4 M 0 7500 0.00 D 2029-06-26 Common Stock 7500 255500 D Stock Option (Right to Buy) 0.34 2020-12-28 4 M 0 6000 0.00 D 2020-05-19 2029-07-14 Common Stock 6000 31766 D Stock Option (Right to Buy) 0.16 2020-12-28 4 M 0 6000 0.00 D 2020-05-19 2029-05-23 Common Stock 6000 56042 D This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 29, 2020. Represents the weighted average sale price of the shares sold from $68.73 to $69.725 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3. Represents the weighted average sale price of the shares sold from $69.73 to $70.52 per share. The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Senior Vice President, Portfolio Management and Corporate Development /s/ Tara Condon, Attorney-in-Fact 2020-12-29